Findings from continued analyses of data from 1,100-patient clinical study identify additional metabolic subtypes that may indicate increased risk of ASD diagnosis
Findings from continued analyses of data from 1,100-patient clinical study identify additional metabolic subtypes that may indicate increased risk of ASD diagnosis
MADISON, Wis.--(BUSINESS WIRE)-- NeuroPointDX, a business unit of Stemina Biomarker Discovery, today announced the company will present additional data from the continued analysis of the Children’s Autism Metabolome Project (CAMP), its large, comprehensive clinical study. The data will be presented in a poster session at the International Society for Autism Research (INSAR) 2019 Annual Meeting taking place from May 1-4, 2019 in Montreal, Canada.
Poster Presentation Details:
Poster Title: Identification of Neurotransmitter-Associated Metabotypes: Further Stratification of the Children’s Autism Metabolome Project ASD Subjects
Session: Biomarkers (molecular, phenotypic, neurophysiological, etc.)
Abstract ID Number: 32033
Poster Board Number: 27
Session Date: Saturday, May 4, 2019
Session Time: 11:30 AM - 1:30 PM
Location: Palais des congres de Montreal, Room: 710
About NeuroPointDX
NeuroPointDX, a business unit of Stemina Biomarker Discovery, is bringing a precision medicine approach to the diagnosis and treatment of neurological disorders through the application of world-class metabolomics. The company’s current focus is autism spectrum disorder (ASD). NeuroPointDX has developed and is commercializing testing panels to aid in the early diagnosis of ASD through its CLIA-certified laboratory.
The NPDX ASD test identifies children with specific metabolic subtypes associated with ASD. The test may be used to screen children as young as 18 months. The NPDX ASD test also provides metabolic information that may be used to inform a more precise treatment strategy for a child with ASD.
The metabolic subtypes were identified and validated in children 18-48 months old in the Children’s Autism Metabolome Project (CAMP), the largest clinical study of metabolism of children with ASD conducted to date.
For more information, please visit our website at http://www.neuropointdx.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190429005179/en/
Contacts
Contact:
Elizabeth Donley, CEO
NeuroPointDX & Stemina Biomarker Discovery
info@neuropointdx.com
608-577-9209
For Media:
Michelle Linn
Bioscribe, Inc.
michelle@bioscribe.com
774-696-3803
Source: NeuroPointDX
View this news release online at:
http://www.businesswire.com/news/home/20190429005179/en
